MedPath

Palbociclib for the Treatment of Estrogen Receptor ...

Palbociclib, a CDK4/6 inhibitor, significantly improves progression-free survival in ER+ HER2- metastatic breast cancer when combined with letrozole, compared to letrozole alone. FDA granted accelerated approval based on phase II trial results. Ongoing studies aim to confirm efficacy and explore biomarkers for better patient selection.

Related Clinical Trials

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

Reference News

pmc.ncbi.nlm.nih.gov
Palbociclib for the Treatment of Estrogen Receptor ...

Palbociclib, a CDK4/6 inhibitor, significantly improves progression-free survival in ER+ HER2- metastatic breast cancer when combined with letrozole, compared to letrozole alone. FDA granted accelerated approval based on phase II trial results. Ongoing studies aim to confirm efficacy and explore biomarkers for better patient selection.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy